Hosit FCM 750mg Injection contains Ferric Carboxymaltose, a parenteral iron preparation indicated for the treatment of iron deficiency anemia when oral iron preparations are ineffective or cannot be used. This formulation provides a controlled release of iron, facilitating rapid replenishment of iron stores and correction of anemia. Hosit FCM 750mg Injection is particularly beneficial in patients with chronic kidney disease, postpartum anemia, or those undergoing chemotherapy, where iron demands are elevated or absorption is impaired. The injection is administered intravenously, allowing for a high dose of iron to be delivered in a single session, thereby improving patient compliance and reducing the need for multiple administrations. Ferric Carboxymaltose is well tolerated, with a low risk of hypersensitivity reactions compared to older iron formulations. Common adverse effects may include transient headache, nausea, dizziness, or injection site reactions. Prior to administration, patients should be evaluated for iron overload conditions and hypersensitivity to iron products. Monitoring of hemoglobin levels and iron parameters is recommended to assess therapeutic response and avoid iron overload. Hosit FCM 750mg Injection offers an effective and convenient option for rapid iron repletion in appropriate clinical settings.